Baricitinib in combination with remdesivir reduces time to recovery in hospitalised patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial

Researchers noted statistically significant ~ 1-day reduction in median recovery time for overall patient population on baricitinib plus remdesivir vs. remdesivir. Lilly plans to discuss potential for emergency use authorisation with FDA and with other regulatory agencies.

Biospace Inc.